Brokerages expect that Teladoc Inc (NYSE:TDOC) will report sales of $76.14 million for the current quarter, according to Zacks. Ten analysts have provided estimates for Teladoc’s earnings, with the lowest sales estimate coming in at $75.50 million and the highest estimate coming in at $76.58 million. Teladoc posted sales of $37.40 million in the same quarter last year, which suggests a positive year-over-year growth rate of 103.6%. The business is expected to report its next earnings report after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Teladoc will report full-year sales of $76.14 million for the current year, with estimates ranging from $231.70 million to $232.72 million. For the next financial year, analysts forecast that the business will post sales of $355.78 million per share, with estimates ranging from $352.90 million to $358.44 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Teladoc.
Several analysts have recently issued reports on the stock. Canaccord Genuity boosted their price objective on shares of Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. ValuEngine raised shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Citigroup assumed coverage on shares of Teladoc in a research note on Thursday, January 4th. They set a “buy” rating for the company. KeyCorp reissued a “buy” rating and set a $39.00 price objective on shares of Teladoc in a research note on Monday, December 4th. Finally, Jefferies Group assumed coverage on shares of Teladoc in a research note on Friday, January 26th. They set a “buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.43.
In related news, CEO Jason N. Gorevic sold 100,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Hirschhorn sold 30,000 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $989,700.00. Following the sale, the chief financial officer now directly owns 5,203 shares of the company’s stock, valued at $171,646.97. The disclosure for this sale can be found here. 4.47% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in TDOC. Nationwide Fund Advisors boosted its position in Teladoc by 126.7% during the 2nd quarter. Nationwide Fund Advisors now owns 30,495 shares of the health services provider’s stock worth $1,058,000 after purchasing an additional 17,046 shares during the period. New York State Common Retirement Fund boosted its position in Teladoc by 74.2% in the 2nd quarter. New York State Common Retirement Fund now owns 67,959 shares of the health services provider’s stock valued at $2,358,000 after buying an additional 28,944 shares during the last quarter. Northern Trust Corp boosted its position in Teladoc by 96.8% in the 2nd quarter. Northern Trust Corp now owns 677,949 shares of the health services provider’s stock valued at $23,525,000 after buying an additional 333,452 shares during the last quarter. Vanguard Group Inc. boosted its position in Teladoc by 11.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after buying an additional 314,646 shares during the last quarter. Finally, California Public Employees Retirement System purchased a new position in Teladoc in the 2nd quarter valued at about $260,000.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.